Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$66.50 – $100.00
23% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $669.2M | $706.3M | $881.3M | $1.24B | $1.36B | $1.15B | $1.19B | $1.19B |
| Cost of revenue | $213.4M | $217.6M | $278.4M | $412.9M | $460.5M | $407.0M | $403.7M | $421.8M |
| Gross profit | $455.8M | $488.7M | $602.9M | $824.8M | $900.6M | $741.2M | $781.7M | $772.7M |
| Gross margin | 68.1% | 69.2% | 68.4% | 66.6% | 66.2% | 64.6% | 65.9% | 64.7% |
| R&D | $45.1M | $47.9M | $50.8M | $70.1M | $96.9M | $90.9M | $91.6M | $70.3M |
| Operating income | $204.5M | $217.9M | $324.2M | $419.5M | $351.3M | $216.3M | $258.3M | $269.6M |
| EBITDA | $254.2M | $273.1M | $383.6M | $504.6M | $479.7M | $333.4M | $399.0M | $364.3M |
| Net income | $158.1M | $175.7M | $247.9M | $311.0M | $240.9M | $159.8M | $188.1M | $155.6M |
| Net margin | 23.6% | 24.9% | 28.1% | 25.1% | 17.7% | 13.9% | 15.9% | 13.0% |
| EPS (diluted) | 2.85 | 3.20 | 4.50 | 5.40 | 4.15 | 2.87 | 3.37 | 2.77 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $1.2B | $4.44 | $3.89–$4.98 | 2 |
| 2027 | $1.3B | $4.93 | $4.22–$5.63 | 2 |
| 2028 | $1.4B | $5.55 | $5.44–$5.68 | 1 |
| 2029 | $1.5B | $5.52 | $5.40–$5.64 | 1 |
Forward consensus · source: Financial Modeling Prep
DIASORIN S.R.L.
No one on the platform currently holds DSRLF.
No tracked institution reports a position in DSRLF as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-05-19 | $1.3000 | 2026-05-20 |
| 2025-05-20 | $1.2000 | 2025-05-21 |
| 2024-05-20 | $1.1500 | 2024-05-22 |
No one on the platform has traded DSRLF yet.
| $5.6B |
| — |
| GZPHFGuangzhou Baiyunshan Pharmaceutical Holdings Company Limited | $2.34 | +0.00% | $6.2B | — |
| OPHLFOno Pharmaceutical Co., Ltd. | $13.50 | +0.00% | $6.3B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 21.0× earnings vs its 32.3× historical median P/E.
Fair value ≈ $114.46 · price $74.25 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.